BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine
demonstrate high efficacy, but surveillance studies are essential to examine the long-term …

abstract Background. Human papillomavirus (HPV) vaccine effectiveness and herd
protection are not well established in community settings. Our objective was to determine …

OBJECTIVES: The aims of this study were to compare prevalence rates of human
papillomavirus (HPV) in young women before and after HPV vaccine introduction to …

Importance Rates of human papillomavirus (HPV) infection have decreased since the
introduction of HPV vaccines in populations with high vaccine uptake. Data are limited for …

BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …

Background Although over a hundred million dollars have been invested in offering free
quadrivalent human papillomavirus (HPV) vaccination to young girls in Ontario, there …

In the United States, human papillomavirus (HPV) vaccination is recommended for 11 or 12
year old girls, with catch-up vaccination through age 26 years. Data are available for women …

Since human papillomavirus (HPV) vaccine was first introduced for females in the United
States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed …

To evaluate receipt of≥ 1 dose of HPV vaccine by age 13 years among adolescent girls,
data during 2007–2013 NIS-Teen survey years were combined and analyzed by birth …

The quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for
administration among 9–26-year-old males and females, with routine vaccination …